Tue, 05 Jan 2016 08:00:00 ESTThe invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.
Tue, 29 Dec 2015 08:00:00 ESTCoatings for medical devices, methods of making the coatings, and methods of using them are described.
Tue, 10 Nov 2015 08:00:00 ESTThe invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
Tue, 27 Oct 2015 08:00:00 EDTThe present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Tue, 06 Oct 2015 08:00:00 EDTA manufacturing process for the preparation of radiolabeled compounds of formula (I) includes reacting compounds of formula (II) with a source of readionuclide of a halogen in the presence of an oxidant under acidic condition, wherein: *I is 123I, 124I, 125I or 131I;R is lower alkyl, optionally substituted with one or more fluorine atoms;Q is C(O), O, NR′, S, S(O)2, C(O)2, (CH2)p;Y is C(O), O, NR′, S, S(O)2, C(O)2, (CH2)p;R′ is H, C(O), S(O)2, C(O)2;Z is H, C1-C4 alkyl, benzyl, substituted benzyl or trialkylsilyl;m is 0, 1, 2, 3, 4 or 5;n is 0, 1, 2, 3, 4, 5 or 6; andp is 0, 1, 2, 3, 4, 5 or 6.
Tue, 22 Sep 2015 08:00:00 EDTDisclosed is a method capable of improving the skin regeneration effect of medicinal materials through double boiling using an earthenware pot. The method shows an excellent skin regeneration effect, and the extract of medicinal materials obtained therethrough can be variously applied in the fields of cosmetics, health foods or medicine.
Tue, 11 Aug 2015 08:00:00 EDTThe present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Tue, 28 Jul 2015 08:00:00 EDTNovel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Tue, 28 Jul 2015 08:00:00 EDTAntibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
Tue, 28 Jul 2015 08:00:00 EDTThe present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above.
Tue, 21 Jul 2015 08:00:00 EDTThe present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Tue, 07 Jul 2015 08:00:00 EDTThe present invention aims at solving the problems of conventional methods for producing an 18F-labeled compound, that is, the problem of purification of a compound in a liquid phase synthesis method and the problem of an insufficient yield due to the reduction of reactivity in a solid phase synthesis method. There is provided a method for producing an 18F-labeled compound including: allowing a high molecular compound containing a residue of a precursor compound to be labeled and a residue of a phase transfer catalyst in the molecule thereof to react with 18F−; and removing the 18F-labeled compound from the high molecular compound.
Tue, 16 Jun 2015 08:00:00 EDTThe present invention provides probiotic compositions suitable for relieving symptoms associated with gastrointestinal disorders. In particular, the present invention provides compositions and methods to relieve symptoms associated with functional bowel disorders, irritable bowel syndrome, functional diarrhea, functional bloating, and other symptoms.
Tue, 16 Jun 2015 08:00:00 EDTProvided herein are herbicide granules containing non-petroleum derived built-in adjuvant.
Tue, 26 May 2015 08:00:00 EDTThe invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
Tue, 26 May 2015 08:00:00 EDTThe invention discloses novel morphology shifting micelles and amphiphilic coated metal nanofibers. Methods of using and making the same are also disclosed.
Tue, 26 May 2015 08:00:00 EDTA pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders.
Tue, 26 May 2015 08:00:00 EDTThe present invention relates to a skin cleanser composition capable of providing an excellent frictional resistance feeling during rinsing and capable of giving an excellent silky feeling with moisturization to the skin after drying, and to a method for producing the composition. The skin cleanser composition contains a cat ionized hydroxypropyl cellulose (A) and a surfactant (B), and the cationized hydroxypropyl cellulose (A) has an anhydroglucose-derived main chain, and has a degree of substitution with cationized ethyleneoxy group of from 0.01 to 3.0 and a degree of substitution with propyleneoxy group of from 0.01 to 2.9.
Tue, 26 May 2015 08:00:00 EDTThe present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
Tue, 26 May 2015 08:00:00 EDTProvided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof.
Tue, 26 May 2015 08:00:00 EDTThe present disclosure provides novel mannanase variants which have an amino acid sequence that varies from that of the parent/wild type Trichoderma reesei mannanase, and which have one or more advantageous properties like improved thermo stability; temperature/activity profile; pH/activity profile; specific activity; and pH/protease-sensitivity. The novel mannanase variants are useful and used in alcohol fermentations processes and/or productions, for coffee extraction and the processing of coffee waste, as a supplement to food and feed, for enzyme aided bleaching of paper pulps, as bleaching and/or desizing agent in textile industry, for oil and gas well stimulation by hydraulic fracturing, as detergent, as baking ingredients, for removal of biofilms and in delivery systems, for grain processing or for the processing of renewable resources intended for the production of biological fuels, and in the textile, oil drilling, cleaning, laundering, detergent, and cellulose fiber processing industries.
Tue, 26 May 2015 08:00:00 EDTA method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.
Tue, 26 May 2015 08:00:00 EDTThe present invention relates to the ameliorating effects of C3G (Cyanidin-3-O-β-d-glucopyranoside) on diabetic erectile dysfunction. In particular, the present invention relates to a pharmaceutical composition and food composition for preventing or treating diabetic erectile dysfunction comprising C3G. In addition, the present invention relates to a pharmaceutical composition and food composition for preventing or treating diabetic erectile dysfunction comprising extract of mulberry containing C3G.
Tue, 26 May 2015 08:00:00 EDTA process for the production of nanocrystals or amorphous nanoparticles of actives (nanomaterials), especially from the peels of grapes. A dispersion of a micrometer-sized material in a solution of surfactant or a steric stabilizer is first provided. The macrosuspension is then stirred for at least 1 minute at a rotational speed above 500 rpm using a rotor-stator mixer. The stirred mixture is passed through a jet stream or piston-gas type high pressure homogenizer. The nanomaterials produced can be incorporated into formulations for use as nutraceutical, nutritional supplement, or as supportive treatment in medical therapy. The active can be derived from the peels of grapes.
Tue, 26 May 2015 08:00:00 EDTDisclosed are compositions that include Docynia delavajy extract, Elaeagnus lanceolatus extract, or a combination of such extracts.
Tue, 26 May 2015 08:00:00 EDTThe present invention concerns various compositions comprising the essential oil of Origanum compactum or of Aniba rosaeodora or one of their constituents, preferably a major constituent, for use in the targeted treatment and prevention of keratoses in the transformation phase and of carcinomas originating from these keratoses, and more particularly of keratoses induced by solar radiation on the skin of a subject. More particularly, the present invention concerns compositions based on the essential oil of oregano or of rosewood, or on linalool, thymol or carvacrol.
Tue, 26 May 2015 08:00:00 EDTThis disclosure relates to a composition for prevention or treatment of neurodegenerative disease comprising longan arillus extract, or combined extract comprising longan arillus. The composition exhibits remarkably excellent prevention or treatment effect of neurodegenerative disease by containing longan arillus extract or combined extract comprising longan arillus, and particularly, it may effectively prevent or treat neurodegenerative disease by significantly protecting dopaminergic neurons from neurotoxicity due to MPTP selectively acting on dopaminergic nervous system and neurotoxicity due to aggregation of alpha-synuclein proteins.
Tue, 26 May 2015 08:00:00 EDTCompositions and methods for treating diabetes are presented herein. In particular, the present disclosure teaches compositions and methods for treating diabetes utilizing a gastrointestinal microbiome modulating composition.
Tue, 26 May 2015 08:00:00 EDTA method of treating prostate cancer by administering a pharmaceutically-acceptable amount of a crude extract of the indigenous Jamaican plant Ball Moss (Tillandsia Recurvata) comprising one or more cycloartane isolates, and the isolates used in the method for eliciting thereby a kinase inhibitory response of prostate cancer cells by selectively inhibiting MRCKα kinase and angiogenesis of (growth of new blood vessels) to reduce the viability of prostate cancer cells. The method and compounds holds promise as a chemopreventive agent, without causing excessive damage to normal cells.
Tue, 26 May 2015 08:00:00 EDTA botanical composition made from a plurality of plant materials selected from Gota Kola (Centella asiatica), Turmeric Root (Curcuma longa), White Willow (Salix alba), Rosehips (Rosa canina), Hibiscus (Hibiscus sabdariffa), Evening Primrose (Oenothera biennis), and Bilberry (Vaccinium myrtillus), or phytochemicals or extracts or oils derived from the plant materials has beneficial application in addressing retinopathy and recurring peripheral neuropathy. The botanical composition can include a number of additional agents such as antioxidants, benfotiamine, thiamine (vitamin B1), and lipoic acid.
Tue, 26 May 2015 08:00:00 EDTCanola protein isolates are provided which contain both albumin and globulin protein fractions that are soluble, transparent and heat stable in an acidic aqueous environment. The canola protein isolates are completely soluble in water at low pH, low in phytic acid and useful in products for human consumption, pet foods and aquaculture.
Tue, 26 May 2015 08:00:00 EDTCompositions for reducing the appearance of wrinkles, reducing the effects of aging and/or improving the appearance of skin. The composition may include at least one fluorinated perfluorocarbon; stem cells from at least one plant species; and at least one peptide complex that reduces release of acetylcholine. Other embodied compositions include at least one collagen stimulating peptide; at least one anti-inflammatory compound; and at least one skin tightening agent.
Tue, 26 May 2015 08:00:00 EDTThe invention provides methods for isolating and enhancing the levels of jasmonates from cacao plant sources. In a preferred embodiment, jasmonic acid and 12-hydroxy jasmonate sulfate are detected in various cocoa products, and the levels of these compounds can be manipulated to increase the beneficial health effects of a food product made with the cocoa products The invention includes methods to prepare edible products containing cocoa jasmonates.
Tue, 26 May 2015 08:00:00 EDTThis invention relates, e.g., to a composition comprising two or more of: (a) N-acetylcysteine and/or (b) simethicone and/or (c) a docusate salt. In one embodiment of the invention, the amounts of (a) and/or (b) and/or (c) are effective, when the composition is administered into a colon of a subject undergoing colonoscopy, to cleanse a region of the colon in the visual field of the colonoscope so that the region contains no adherent stool or intestinal secretions obscuring the visual field. Methods for using this or other compositions of the invention, e.g. to cleanse the colon of a subject in order to enhance visualization of the colon during a colonoscopy, are also described, as are kits for carrying out methods of the invention.
Tue, 26 May 2015 08:00:00 EDTThe present invention has an object to provide a flaky particulate material giving skin an excellent smoothness, which is free from whitening problem upon use thereof owing to its high transparency. The present invention also has another object to provide a cosmetic composition containing the flaky particulate material. The present invention relates to flaky particulate material, which has an average coefficient of friction is not more than 0.50, and a total light transmittance is not less than 85%. A particle in the flaky particulate material comprises a substrate particle made of one material selected from the group consisting of mica, a synthetic mica, sericite, talc, barium sulfate and aluminum oxide. The present invention provides a flaky particulate material that gives skin excellent smoothness, a natural tone, and a matt appearance. The flaky particulate material of the present invention gives a cosmetic composition which provides great comfort of use, and an excellent appearance.
Tue, 26 May 2015 08:00:00 EDTDescribed herein are materials and methods for increasing the osteoconductivity of a bone graft material, reducing the risk of infection at a surgical site, and increasing hemostasis. The bone graft materials described herein contain calcium phosphate and a form of chitin. In another embodiment the bone graft materials further comprises collagen. Chitin has been demonstrated to provide increased rate of new calcium phosphate growth, increased hemostasis, as well as antimicrobial properties. Various methods for manufacturing the bone graft materials described herein are also contemplated.
Tue, 26 May 2015 08:00:00 EDTDisclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity.
Tue, 26 May 2015 08:00:00 EDTThe present disclosure is directed to compositions comprising encapsulated particles of diethylenetriaminepentaacetate (DTPA) and a zinc salt such as zinc acetate, and to pharmaceutical compositions comprising such encapsulated compositions. The present disclosure is also directed to methods of treatment by administering an effective amount of the compositions and pharmaceutical compositions of the present disclosure, to methods of making such encapsulated particle compositions, and to methods of making the corresponding pharmaceutical compositions.
Tue, 26 May 2015 08:00:00 EDTDiscrete micro and nanoscale particles are formed in predetermined shapes and sizes and predetermined size dispersions. The particles can also be attached to a film to form arrays of particles on a film. The particles are formed from molding techniques that can include high throughput and continuous particle molding.
Tue, 26 May 2015 08:00:00 EDTA taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture; b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable pharmaceutically acceptable excipient(s) with aqueous/non-aqueous fluid to obtain a wet mass; c) drying the wet mass to obtain the discrete particles; d) lubricating the discrete particles obtained with a suitable lubricating agent and/or flavor(s).
Tue, 26 May 2015 08:00:00 EDTThe present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
Tue, 26 May 2015 08:00:00 EDTCertain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
Tue, 26 May 2015 08:00:00 EDTA unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
Tue, 26 May 2015 08:00:00 EDTA tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
Tue, 26 May 2015 08:00:00 EDTDisclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Tue, 26 May 2015 08:00:00 EDTAn oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.
Tue, 26 May 2015 08:00:00 EDTPharmaceutical compositions and methods for the treatment of chronic fatigue in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount in combination with therapeutically effective daily amounts of micronutrients, comprising acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS and micronutrient components may be in an oral dosage composition containing a low dosage amount of CNS stimulant such as about 2.5 mg methylphenidate HCl together with about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid.
Tue, 26 May 2015 08:00:00 EDTThe present invention relates to the use of lipid containing particles, such as liposomes, iscom and/or iscom matrix and posintros, comprising at least one lipid and at least one saponin for the preparation of a pharmaceutical for the treatment of cancer. The saponins are preferably from Quillaja Saponaria Molina. Further, the particles are also delivery systems for one or several compounds for cancer treatment with complementary mechanisms. More, the invention discloses kit of parts comprising at least two parts, wherein one part comprising at least one saponin fraction which is hydrophobic having a killing effect on cancer cell; and the other part comprising at least one saponin fraction which is comparatively hydrophilic, stimulating and modulating the immune response.
Tue, 26 May 2015 08:00:00 EDTThe present disclosure relates to a method of melt processing an active agent. The method may include encapsulating an active agent in a first polymer material exhibiting a first processing temperature T1 and forming capsules including the active agent. The method may also include melt processing the capsules with a second polymer material exhibiting a second processing temperature T2, wherein T1>T2.
Tue, 26 May 2015 08:00:00 EDTA special photosensitizer formulation and Photodynamic Therapy method for treating choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) is provided. CNV is a major cause for vision loss in elderly patients. A special drug delivery formulation is used to encapsulate the hydrophobic photosensitizer, preferably a pegylated liposome. This improves the solubility and therapeutic index of the photosensitizers. In one preferred embodiment, a pegylated photoactive agent remains confined in the intravascular compartment of neovasculature for a longer duration. Thus efficient elimination of neovascular proliferation and minimal damage to extravascular tissue and normal vessels is ensured. In this method, a hydrophobic photosensitizer, that is able to photochemically destroy neovessels, is injected into the patient. CNV irradiation with a non-thermal laser follows after a predefined time interval. The excited photosensitizer photocoagulates newly formed blood vessels thereby improving the vision and preventing further loss of vision.